Skip to main content

Published locations for Ibrutinib + venetoclax: High-risk features don’t lessen CLL response

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib + venetoclax: High-risk features don’t lessen CLL response

User login

  • Reset your password
  • /content/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll-response
  • /fedprac/article/263586/cll/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll-response
  • /hematologynews/article/263586/cll/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll-response
  • /fedprac/avaho/article/263586/cll/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll-response
  • /hematology-oncology/article/263586/cll/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll
  • /b-cell-lymphoma-icymi/article/263586/cll/ibrutinib-venetoclax-high-risk-features-dont-lessen-cll